| | Taking the Fight to Rare Cancers Beating rare cancers demands expertise in oncology and rare diseases. Our white paper shows how adaptive design, study committees, and cross-industry cooperation are fueling real progress. Premier Research. Built for Biotech℠ |
Today's Rundown Chasing AbbVie, Gilead files for approval of filgotinib in Japan Chinese infectious disease biotech Ascletis nabs Novartis exec as CSO Cygnal officially uncloaks with $65M and exoneural approach to cancer [Sponsored] Thwarting Subjectivity in Clinical Trials Novartis' Xolair follow-up banishes hives in 42% of patients with chronic hives Merck taps 4D pharma for bacterial vaccine R&D project Novartis takes on Regeneron, Roche blockbusters with Beovu approval Featured Story | | | Tuesday, October 8, 2019 Gilead Sciences has filed for approval of JAK1 inhibitor filgotinib in Japan. The submission moves Gilead a step closer to selling the Galapagos-partnered drug to rheumatoid arthritis patients in the country. |
|
|---|
|
Top Stories Tuesday, October 8, 2019 After poaching an ex-Merck exec to run its R&D, Chinese biotech Ascletis has raided another U.S. Big Pharma for its new chief scientific officer. Tuesday, October 8, 2019 When Roche veteran Pearl Huang landed at Cygnal Therapeutics in January, the company painted a broad picture of its exoneural approach to treating cancer. Now, as Flagship Pioneering officially launches Cygnal, the startup is filling in some details. Monday, October 7, 2019 A clinical trial is a measurement system, but too often, we fail to calibrate the most significant of measurement instruments: trial participants. Tuesday, October 8, 2019 Two doses of Novartis’ new treatment for chronic hives cleared the skin of more patients than Xolair, its Roche-partnered asthma drug. The highest dose of the drug banished hives in 51% of patients, compared to 26% of patients taking Xolair. Tuesday, October 8, 2019 Merck has teamed up with 4D pharma to develop bacterial strains as vaccines. The deal gives Merck the chance to pick up three candidates against undisclosed indications for an upfront fee and up to $347.5 million (€316.2 million) in milestones. Tuesday, October 8, 2019 Novartis has its next big drug approval. The FDA on Tuesday approved wet AMD drug Beovu, which will go up against entrenched blockbusters Eylea from Regeneron and Lucentis from Roche. The drug has shown it can match up against Eylea's efficacy and bested the Regeneron drug on other measures. Resources Sponsored by: Medidata Simplified filing, improved oversight, audit readiness: is your eTMF system delivering best-in-class benefits? Sponsored by: Colorcon® Learn about how you better manage product authentication and battle drug counterfeiting with innovative solutions. Sponsored by: Cortellis, a Clarivate Analytics Solution Download this report for full details of Life sciences M&As in the second quarter of 2019 with notes and trends. Sponsored by: Elligo Health Research Find out how it leverages real-world data and novel IntElligo Research Stack™ technology to help researchers battle rising costs, cumbersome processes, and stagnant participation — bridging the gap between research and care. Sponsored by: InformedDNA Download this complimentary guide paper that explores key strategies for a successful genetics-informed clinical trial. Sponsored by: Life Image The time has finally come when medical imaging can be effectively utilized into the RWE process. Read the whitepaper on the best practices for incorporating Real World Imaging.™ Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: BioAnalytix, Inc. Download the White Paper and learn how detailed characterization can guide successful development of gene therapy products. Sponsored by: ON24 Compare digital program performance and audience engagement among your life sciences peers. Sponsored by: Decision Resources Group Clinically Integrated Networks are vehicles for powerful IDNs to extend their influence into the physician sector and play a key role for IDNs trying to pave a path to becoming a self-contained healthcare ecosystem. Sponsored by: Reprints Desk, Inc. Slashing your R&D costs is easier than you think. Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Blue Matter, strategic consultants in the life sciences White paper providing an overview of precision medicine in oncology, as well as a look ahead at future developments and keys to success for pharmaceutical and diagnostics companies. Sponsored by: Outer Edge Technology Find out how outsourcing your IT requirements enhances the bottom line while creating strategic advantage. Sponsored by: Vineti Developing a cell therapy, gene therapy, or personalized cancer vaccine? Modern data management makes a critical difference in operational and regulatory outcomes. This whitepaper will help your team leverage the latest data strategies for success. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. BioBasics: Biotech For The Non-Scientist Oct 22-23, 2019 | San Diego, CA BioImmersion: Biotech for the Non-Scientist October 23-25, 2019 | Chicago, IL 4th FierceBiotech Drug Development Forum October 28-29, 2019 | Boston, MA Drug Development Immersion November 7-8, 2019 | Boston, MA Advanced Therapies: Immunotherapies, Cell Therapies and Gene Therapies November 15, 2019 | Boston, MA Countdown to Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register Now at www.drugstomarket.com/drugbootcamp and start Pre-Boot Camp Preparation | 